Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 29c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
Loss per share - basic and diluted: -0.05
Today's EPS Names:
VIVO, BIOX, PMCB, More
Financial Fact:
Loss per share - basic and diluted: -0.05
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.68, $0.29 better than the analyst estimate of $0.39. Revenue for the quarter came in at $146.54 million versus the consensus estimate of $140.22 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2025 revenue of $545-565 million, versus the consensus of $560.7 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
- Activist investor presses Xerox to review financial services arm - Bloomberg
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
